Applied DNA Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023
August 10, 2023 at 04:02 pm EDT
Share
Applied DNA Sciences, Inc. reported earnings results for the third quarter and nine months ended June 30, 2023. For the third quarter, the company reported revenue was USD 2.92 million compared to USD 4.3 million a year ago. Net loss was USD 3.1 million compared to USD 1.12 million a year ago. Basic loss per share from continuing operations was USD 4.8 compared to USD 2.6 a year ago.
For the nine months, revenue was USD 12.59 million compared to USD 14.61 million a year ago. Net loss was USD 6.35 million compared to USD 7.6 million a year ago. Basic loss per share from continuing operations was USD 9.8 compared to USD 18.8 a year ago.
Applied DNA Sciences, Inc. is a biotechnology company that develops, and markets deoxyribonucleic acid (DNA) based technology solutions. The Company is utilizing its LinearDNA large-scale polymerase chain reaction (PCR) based manufacturing platform. The Companyâs proprietary platform produces large quantities of DNA for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets and for supply chain security, anti-counterfeiting and anti-theft technology purposes. It also develops PCR-based molecular in vitro diagnostics for covid-19. In addition, under its wholly owned subsidiary, Applied DNA Clinical Labs, LLC, the Company is offering a high-throughput turnkey solution for population-scale Covid-19 testing marketed as safeCircle. safeCircle utilizes the Companyâs Covid-19 Diagnostic Tests and is designed to look for infection within defined populations or communities utilizing high throughput testing methodologies.
APPLIED DNA SCIENCES, INC. 
